AuthorisedPhase II and Phase III (Integrated)Interventional

Test-Retest Evaluation of [18F]F-AraG in Lung Tumors (TREAT)

This research study, known as TREAT, is investigating a special type of scan for people with lung cancer. It uses a unique substance called [18F]F-AraG which helps doctors see what's happening inside lung tumours. The main goal is to test how reliable and consistent this scan is. Doctors want to see if the scanner gives similar results when used at different times. If successful, this scanning method could potentially help doctors better understand how lung tumours are responding to treatments like NELARABINE. This could allow for more informed decisions about a patient's care. It's a 'Phase II and III' study, meaning it's still in the stages of carefully testing the method's effectiveness and safety.

At a glance

Status

Authorised

Phase

Phase II and Phase III (Integrated)

Sponsor

Amsterdam UMC Stichting

Enrolment target

Start

27 Jan 2026

Lung Cancer

What is this study about?

This research study, called TREAT, is designed to investigate a new way of looking at lung tumours using a special scanning process. The aim is to make sure this scanning method is accurate and reliable for people with lung cancer. Doctors hope this new scan will help them tell if a treatment, specifically one called NELARABINE, is working to shrink or slow down the cancer.

To do this, participants will have scans done at different times. Researchers will then compare the pictures from these scans to see if they can consistently measure changes in the tumour. They'll be looking at how brightly the tumour 'lights up' on the scan, which can show how active the cancer cells are. Think of it like taking a photo of something at two different times to see if it has changed, and if the camera is giving you a clear picture each time.

The importance of this study is that if this scanning method proves to be accurate and consistent, it could provide doctors with a better tool to monitor lung cancer. This could mean doctors might be able to tell sooner if a treatment is effective, helping them to make the best possible decisions for each patient's care. It's an important step in finding more effective ways to manage lung cancer.

Key takeaways

The TREAT study is testing a new scan for lung cancer.
It aims to see how consistent and reliable the scan is at different times.
The scan uses a special substance called [18F]F-AraG.
The study involves patients receiving NELARABINE treatment.
Results could help doctors better understand how lung tumours respond to treatment.

Who may be eligible?

To be considered for this study, you must be an adult, aged 18 years or older, with lung cancer. The study is open to both men and women.

Beyond these basic requirements, there will be other specific medical criteria that your specialist cancer doctor will need to check. These typically include things like your overall health, any other medical conditions you might have, and specific details about your lung cancer.

These detailed checks are in place to make sure that the study is safe for you, and that the results of the study will be as clear and useful as possible. Your doctor will be able to tell you if this study might be suitable for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have a diagnosis of lung cancer?
Are you generally well enough for hospital visits and scans?
Are you able to follow study instructions for scans and appointments?
Has your specialist cancer doctor confirmed you meet all other medical requirements?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you would likely have a few visits to the hospital or clinic. These visits would include undergoing the special scans using the [18F]F-AraG substance. You would also receive the treatment called NELARABINE as part of your care. Researchers will need to take measurements from your scans at two different times to compare them. The exact number of visits, tests, and the total length of your participation would be explained in detail by the study team, as it can vary. There would also be follow-up appointments to monitor your health and how you are responding.

Potential risks and benefits

Taking part in a study like this could offer potential benefits, such as receiving treatment with NELARABINE and having close monitoring of your lung cancer. While the special scan aims to be a helpful tool, there might be some risks involved, such as potential side effects from the scan's substance or the treatment. These will be thoroughly explained to you, including any discomfort from the scans or possible reactions. It's important to remember that you are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Netherlands

Common questions

What is the TREAT study about?

It's a study testing how well a new scanning method can reliably measure changes in lung tumours for people with lung cancer.

What is [18F]F-AraG?

It's a special substance used in the scans that helps doctors see activity in lung tumours.

What is NELARABINE?

It's a treatment that is being given to participants as part of their care in this study.

Who can take part?

Adults aged 18 years or older with lung cancer, both men and women, may be eligible. Your doctor will check other medical details.

Will taking part affect my normal treatment?

No, your decision to join or leave the study will not affect the standard medical care you receive.